Peptide merchant assessment: evidence beyond a research-only label

Begin with the actual product and customer

A peptide business should explain what it sells, who buys it and how the product is presented. Research supply, a medicinal product and a consumer-facing wellness offer are not interchangeable descriptions. A payment assessment needs a truthful account of the activity rather than a label chosen because it sounds easier to underwrite.

Prepare the exact catalogue, contracting entity, supplier relationships and customer markets. Identify the intended purchaser types and the controls used to support that model. If a product’s classification is unresolved, obtain appropriate specialist advice before treating it as ready for payment acceptance.

Review the whole presentation

Product names and disclaimers are only part of the evidence. Review website descriptions, advertisements, affiliate content, support responses and accessories together. The complete presentation should be consistent with the business’s stated intended use.

In its August 2026 warning letter to Peak Performance Peptides, FDA explained that website evidence contradicted research-only and non-human-consumption disclaimers for the products discussed. Those are case-specific findings, not a blanket ruling on every peptide seller. The operational lesson is that a disclaimer should not be treated as a substitute for reviewing the actual offer and its implications.

Do not attempt to solve a classification issue by hiding claims from a reviewer while leaving them in customer communications. The business should resolve the underlying inconsistency. Accurate disclosure supports a meaningful assessment and avoids a payment arrangement based on an incomplete description.

Connect documents to individual products

A certificate of analysis can provide information about testing, but it does not by itself establish permission to market a product for a particular use. Keep analytical evidence separate from the assessment of legal classification and market access. Each document should have a clear purpose.

Build a product file with supplier identity, relevant batch references, available test information and the evidence supporting the proposed commercial activity. Check that documents actually refer to the items being sold. A generic supplier brochure should not be represented as product-specific verification.

Where products or suppliers change, update the file before expanding the live catalogue. Assign responsibility for checking document consistency and resolving gaps. The process should be practical enough to continue after onboarding, not a one-time collection assembled for an application.

Make customer and fulfilment controls visible

Explain how the business identifies its intended customer group and handles orders that do not fit the stated model. A research-supply description should correspond to the actual sales process. Avoid asserting that a simple customer declaration conclusively establishes eligibility or intended use.

Describe storage, fulfilment, delivery exceptions and returns accurately, with specialist input where necessary. The payment reviewer needs to understand what happens after the sale and how the merchant responds when it cannot deliver as promised. Do not include medical-use instructions or unsupported health claims in the payment brief.

Maintain a connection between the order, product batch where relevant and customer communication. This supports investigation of complaints and operational errors. Protect sensitive commercial and customer information, and agree secure channels for detailed onboarding evidence.

Assess markets separately

A product description accepted in one context should not be assumed valid in every destination. Map the proposed products to the markets and purchaser types the business intends to serve. Identify where qualified advice or further documentation is needed before launch.

Payment coverage is a separate question. A card, wallet or digital-asset method does not make an otherwise unacceptable activity permissible. Present the same accurate business model to each prospective provider rather than changing the description to suit the application route.

Prepare a focused underwriting brief

Include the legal entity, website, precise catalogue, intended use, customer markets, expected volumes and processing history. Explain material refunds, complaints or previous account restrictions truthfully. Separate completed controls from improvements still in progress.

Ask the provider which activities it can assess and what further evidence it needs. Do not interpret receipt of documents as approval. The final scope should be clear before integration or marketing promises about payment availability are made.